title: A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses.
abstract: Broad-spectrum antiviral drugs are urgently needed to treat individuals infected with new and re-emerging viruses, or with viruses that have developed resistance to antiviral therapies. Mammalian natural host defense peptides (mNHP) are short, usually cationic, peptides that have direct antimicrobial activity, and which in some instances activate cell-mediated antiviral immune responses. Although mNHP have potent activity in vitro, efficacy trials in vivo of exogenously provided mNHP have been largely disappointing, and no mNHP are currently licensed for human use. Mastoparan is an invertebrate host defense peptide that penetrates lipid bilayers, and we reasoned that a mastoparan analog might interact with the lipid component of virus membranes and thereby reduce infectivity of enveloped viruses. Our objective was to determine whether mastoparan-derived peptide MP7-NH2 could inactivate viruses of multiple types, and whether it could stimulate cell-mediated antiviral activity. We found that MP7-NH2 potently inactivated a range of enveloped viruses. Consistent with our proposed mechanism of action, MP7-NH2 was not efficacious against a non-enveloped virus. Pre-treatment of cells with MP7-NH2 did not reduce the amount of virus recovered after infection, which suggested that the primary mechanism of action in vitro was direct inactivation of virus by MP7-NH2. These results demonstrate for the first time that a mastoparan derivative has broad-spectrum antiviral activity in vitro and suggest that further investigation of the antiviral properties of mastoparan peptides in vivo is warranted.
authors.affiliation: Duke University Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, United States.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Sample
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Hudak
authors.forename: Brice E
authors.initials: BE
authors.lastname: Barefoot
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Koci
authors.forename: Moses S
authors.initials: MS
authors.lastname: Wanyonyi
authors.forename: Soman
authors.initials: S
authors.lastname: Abraham
authors.forename: Herman F
authors.initials: HF
authors.lastname: Staats
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Ramsburg
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D007448:Invertebrates / Q000737:chemistry; D051379:Mice; D008854:Microscopy, Electron; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D014780:Viruses / Q000187:drug effects* / Q000648:ultrastructure; D014862:Wasp Venoms / Q000737:chemistry*
chemical_list: D000998:Antiviral Agents; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D014862:Wasp Venoms; C037500:mastoparan
keywords: Antiviral; Host defense peptide; Mastoparan
references.citation: J Pept Res. 2000 Jan;55(1):51-62
references.pmid: 10667861
references.citation: J Cell Biol. 1988 Jul;107(1):89-99
references.pmid: 2839523
references.citation: Infect Disord Drug Targets. 2011 Jun;11(3):315-36
references.pmid: 21488828
references.citation: Emerg Infect Dis. 2001 Jul-Aug;7(4):675-8
references.pmid: 11585531
references.citation: Biophys J. 2001 Jan;80(1):280-93
references.pmid: 11159401
references.citation: Infect Immun. 1998 Sep;66(9):4222-8
references.pmid: 9712771
references.citation: Clin Exp Immunol. 2012 Apr;168(1):113-24
references.pmid: 22385246
references.citation: J Virol. 2003 Jan;77(1):460-9
references.pmid: 12477851
references.citation: J Pharmacol Exp Ther. 1989 Jul;250(1):329-35
references.pmid: 2473189
references.citation: Chemotherapy. 1991;37(3):206-11
references.pmid: 1889308
references.citation: Crit Rev Immunol. 2000;20(5):407-31
references.pmid: 11145218
references.citation: BMC Microbiol. 2009 Feb 11;9:33
references.pmid: 19208266
references.citation: J Virol. 1979 Nov;32(2):614-22
references.pmid: 501802
references.citation: Regul Pept. 2004 Sep 15;121(1-3):121-8
references.pmid: 15256282
references.citation: FEBS Lett. 1983 Feb 21;152(2):227-30
references.pmid: 6825849
references.citation: J Gen Virol. 1981 Jul;55(Pt 1):109-16
references.pmid: 6170723
references.citation: J Virol. 1998 Jun;72(6):4704-11
references.pmid: 9573234
references.citation: Vaccine. 2008 Nov 11;26(48):6108-18
references.pmid: 18809447
references.citation: Prog Mol Biol Transl Sci. 2009;86:249-98
references.pmid: 20374719
references.citation: J Virol. 1973 Nov;12(5):1173-80
references.pmid: 4128827
references.citation: Biochemistry. 2012 Jun 19;51(24):4898-908
references.pmid: 22630563
references.citation: J Infect Dis. 2007 Sep 15;196(6):835-43
references.pmid: 17703413
references.citation: J Biol Chem. 1988 May 15;263(14):6491-4
references.pmid: 3129426
references.citation: Br J Clin Pharmacol. 2006 Dec;62(6):699-709
references.pmid: 17118125
references.citation: Annu Rev Pharmacol Toxicol. 2012;52:337-60
references.pmid: 22235859
references.citation: Toxicon. 2010 Jun 15;55(7):1213-21
references.pmid: 20096299
references.citation: Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19123-7
references.pmid: 17146053
references.citation: Biochemistry. 2009 Aug 4;48(30):7342-51
references.pmid: 19594111
references.citation: Proc Biol Sci. 2006 Jan 22;273(1583):251-6
references.pmid: 16555795
references.citation: Peptides. 2011 Jul;32(7):1518-25
references.pmid: 21620914
references.citation: J Neurosci. 1997 Aug 15;17(16):6165-78
references.pmid: 9236228
references.citation: N Engl J Med. 2004 Mar 18;350(12):1179-88
references.pmid: 14985470
references.citation: Peptides. 2008 Jan;29(1):1-6
references.pmid: 18045738
references.citation: Eur J Cell Biol. 1993 Feb;60(1):163-78
references.pmid: 8385018
references.citation: N Engl J Med. 2002 Oct 10;347(15):1199-200
references.pmid: 12374882
references.citation: J Clin Invest. 2005 Mar;115(3):765-73
references.pmid: 15719067
references.citation: Eur J Clin Invest. 2003 Jan;33(1):82-7
references.pmid: 12492457
references.citation: Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):953-8
references.pmid: 14722355
references.citation: Int J Antimicrob Agents. 2004 Apr;23(4):382-9
references.pmid: 15081088
references.citation: J Leukoc Biol. 1998 Jan;63(1):94-100
references.pmid: 9469478
references.citation: J Virol. 1999 Feb;73(2):1503-17
references.pmid: 9882356
references.citation: J Bacteriol. 2005 Aug;187(15):5387-96
references.pmid: 16030233
references.citation: Virol J. 2010 May 12;7:95
references.pmid: 20462412
references.citation: Annu Rev Microbiol. 1987;41:103-26
references.pmid: 3318666
references.citation: Nat Rev Microbiol. 2005 Jan;3(1):13-22
references.pmid: 15608696
references.citation: J Neurochem. 1995 Dec;65(6):2425-31
references.pmid: 7595536
references.citation: J Virol. 1981 Jan;37(1):1-6
references.pmid: 7218421
references.citation: J Gen Virol. 1998 Apr;79 ( Pt 4):731-40
references.pmid: 9568968
references.citation: J Virol. 1986 Dec;60(3):1068-74
references.pmid: 3023659
references.citation: Antiviral Res. 2007 Nov;76(2):111-23
references.pmid: 17655941
references.citation: Vaccine. 2009 Dec 10;28(1):79-89
references.pmid: 19819211
references.citation: Apoptosis. 2004 Mar;9(2):145-8
references.pmid: 15004511
references.citation: J Biol Chem. 1995 May 26;270(21):12869-76
references.pmid: 7759545
references.citation: J Immunol. 1999 Dec 15;163(12):6718-24
references.pmid: 10586069
references.citation: J Virol. 2006 Jul;80(14):7028-36
references.pmid: 16809308
references.citation: Int Arch Allergy Immunol. 2003 May;131(1):25-32
references.pmid: 12759486
references.citation: J Immunol. 2004 Feb 1;172(3):1763-7
references.pmid: 14734759